CpG-containing bacterial DNA (which uniquely bypassed the potential adverse effects of live bacterial treatment), was found to be effective against experimental NEC in mice and piglets through inhibition of TLR4 (and activation of TLR9) (76). Here, TLR9 is linked to necrotizing enterocolitis.